Alcon Inc. reports developments in eye care through its Surgical and Vision Care businesses. Company news commonly covers quarterly results, constant-currency sales trends, product-launch momentum and portfolio updates across cataract and vitreoretinal surgical systems, intraocular lenses, contact lenses, lens-care products and ocular health.
Recurring updates also include launches and milestones for products such as Clareon, PanOptix, Vivity, TOTAL30, Precision7, Tryptyr and Unity, along with annual general meeting items, board elections, compensation votes, dividends, share repurchase authorizations, acquisitions, integration costs, R&D spending and other governance or capital-allocation actions.
Alcon (SIX/NYSE: ALC) announces the launch of Pataday Once Daily Relief Extra Strength (olopatadine hydrochloride ophthalmic solution 0.7%) in U.S. stores and online. Approved by the FDA for OTC sales in 2020, this product strengthens Alcon's position in the ocular allergy market, joining the top-selling OTC eye allergy relief brand. Catering to approx. 66 million Americans with ocular allergies, it provides 24-hour relief with just one drop daily. The launch will be supported by extensive advertising campaigns to reach potential users.
Alcon (SIX/NYSE: ALC) has launched the PRECISION1® for Astigmatism, a daily disposable silicone hydrogel contact lens aimed at individuals with astigmatism. This innovative product integrates SMARTSURFACE® technology and features a stable lens-wearing experience with a 99% first fit success rate. The company estimates that toric lenses represent 23% of the $9 billion global contact lens market, presenting significant growth opportunities. Available in the U.S. and set for international rollout in February 2021, the lens aims to capture a market where 41% of patients are astigmatic but only 10% wear toric lenses.
Alcon (SIX/NYSE: ALC) has launched the AcrySof® IQ Vivity™ IOL, a first-of-its-kind non-diffractive extended depth of focus intraocular lens in the U.S., aimed at presbyopia patients undergoing cataract surgery. This innovative lens promises monofocal-quality distance vision with improved intermediate and near vision. With the U.S. cataract surgery market projected to reach 5.4 million by 2025, Vivity expands Alcon's IOL portfolio, enhancing patient options and experience. The lens is already available in several international markets.